Patrin Pharma

Executive Summary

Patrin Pharma is a privately-held generic pharmaceutical company headquartered in San Diego, CA, founded in 2018. The company specializes in developing and commercializing high-quality, cost-effective generic drugs for both OTC and Rx markets. Leveraging deep expertise in product development and long-standing partnerships, Patrin has established a track record of innovative product launches. The company focuses on practical innovation and customer service to differentiate itself in the competitive generic landscape. While specific financials and pipelines are undisclosed, Patrin's strategy of targeting niche generic opportunities with unmet needs positions it for steady growth. The company operates in the highly regulated US generics market, where success hinges on timely ANDA approvals and efficient manufacturing. With no disclosed funding rounds, Patrin likely maintains a lean operation, relying on organic revenue from existing products. Its private status limits public visibility, but the management's industry experience and partnership approach suggest a disciplined growth trajectory. Looking ahead, Patrin's performance will depend on its ability to navigate FDA approvals, manage pricing pressures, and expand its product portfolio.

Upcoming Catalysts (preview)

• Q3 2026ANDA Approval for a Niche Generic Drug60% success
• Q2 2026Exclusive Licensing or Distribution Partnership45% success
• Q4 2026Launch of a New OTC Product50% success